Amos will provide services for Boston Scientific’s urology and women’s health, endoscopy, peripheral interventions and interventional cardiology products, with the exception of the Watchman left atrial appendage occlusion device.
The partnership was reached with Amos and Israeli marketing firm Medison, according to a press release.
Boston Scientific has been making headway around the world, recently announcing the 1st implant of its lead-free S-ICD heart rhythm implant in China, a launching board for broader efforts in Asia.
BSX shares got a boost today, gaining 4.1% to trade at $13.44 as of about 1:45 p.m. The stock has gained 11.7% since the start of the year.